Blog

Pricing Strategy for Fertility & Reproductive Health

by Jason Shafton

Fertility and reproductive health companies manage two pricing motions simultaneously: a per-employee-per-month price sold to HR and benefits leaders, and a per-cycle or bundled price patients experience during treatment. Winston Francois develops pricing architecture that works in both rooms, so a broker's discount request doesn't quietly wipe out your margin.

The Challenge

PEPM pricing and patient pricing are created by separate teams and seldom reconciled

The commercial team sets employer PEPM based on competitive benchmarking and broker feedback, while clinical and product teams set per-cycle or bundle pricing based on cost-to-serve, and the two numbers are almost never checked against each other. A company can win an RFP at an attractive PEPM rate and still lose money on that account the moment its population's IVF utilization runs above the assumption baked into the deal.

Utilization risk stays hidden until the renewal discussion

A generous plan design at a large employer with a young, high-income population can produce utilization rates three or four times what a lean-benefit employer generates, and if pricing doesn't segment for that difference, the highest-utilization accounts become the least profitable ones. By the time finance flags the margin problem, the employer has already built a budget around last year's PEPM, and any correction reads as a price increase instead of a fix.

Broker-led RFP season puts pressure on price before value is established

Brokers run competitive processes that compare PEPM line items across vendors before any buyer has seen the clinical program in action, which trains the sales team to defend on price rather than sell the difference in outcomes or member experience. Every unstructured discount granted to win a broker-run RFP becomes the new floor at the next renewal, and reversing it later looks like the company backing off value it once claimed.

Patient-facing pricing carries reputational stakes that a typical SaaS price change doesn't

A price change on a per-cycle bundle or self-pay option reaches people mid-treatment, at a point in their life with limited tolerance for surprises, so pricing communication failures do more damage here than in almost any other category. Companies that treat patient pricing like a routine SKU update instead of a trust-sensitive disclosure generate support escalations and public complaints that a straightforward price increase would never cause elsewhere.

How We Develop Pricing That Holds

We begin by reconciling the two pricing models with actual cost-to-serve data: what it truly costs to deliver a completed IVF cycle, an egg freezing cycle, or a menopause care episode, mapped against the PEPM revenue collected from the employer whose population uses it. Most companies have only seen this number in aggregate, never by account, which obscures exactly where margin is gained or lost.

Next, we create a tiered PEPM framework that prices according to plan design generosity instead of using one flat rate. An employer providing unlimited cycles with low member cost-share should not pay the same PEPM as one providing a capped, cost-shared benefit. Making that distinction explicit gives the sales team a defensible figure rather than a negotiating position that folds under broker pressure.

For patients, we develop per-cycle and bundle pricing around the actual length of the treatment journey rather than treating it as a subscription. This means modeling revenue per completed journey instead of per month, and pricing self-pay or bundled options to reflect the true cost of a finite, high-touch clinical process rather than an estimate anchored to a competitor's website.

We then establish discount governance: defined guardrails for what an account executive may concede in an RFP without escalation, plus a standard framework for what gets added back – such as reporting cadence, dedicated account support, or expanded network access – when PEPM is discounted below the floor. This shifts discounting from an ad hoc concession to a structured trade.

Finally, we create the renewal playbook: how utilization data is shared with the employer ahead of the renewal conversation, how a PEPM adjustment is positioned as aligned with usage rather than an unexplained increase, and how the sales team protects the account instead of re-litigating the original RFP year after year.

What we deliver

Fertility companies don't sacrifice margin at renewal simply because their PEPM is too low. They lose it because the PEPM was never designed to reflect the true cost of running a generous plan design, making every high-utilization employer a discount the company didn't realize it was offering.

Our Methodology

We structure pricing engagements as a 90-day build within a longer commitment. During the first 30 days, we reconcile cost-to-serve with current PEPM and patient pricing by account, revealing exactly which employer segments and plan designs generate profit and which are subsidized. Over the next 30 days, we develop the tiered PEPM framework, per-cycle bundle model, and discount governance rules, testing them against your existing book of employer accounts before applying them to new deals.

The last 30 days center on rollout: training sales and account management teams on the new framework, creating the renewal narrative for accounts where PEPM must change, and establishing the reporting your team needs to identify utilization drift before it turns into a margin issue.

Following the initial 90 days, we remain embedded through at least one complete RFP and renewal cycle, because pricing frameworks that appear solid on paper often require refinement when confronted with real broker pushback and employer renewal discussions. Most engagements last 6-9 months to encompass a full annual cycle.

The Insights You Want

Right in your inbox. We’ve done the work, and now we’re sharing it with you. Sign up to stay in the loop.

Get The Latest Updates


Enter your email address

Our Working Approach

The first 30 days focus on diagnosis: we gather utilization and cost data by account, join current sales and renewal conversations, and identify where the existing pricing model breaks down. Days 31-60 cover the build: drafting the tiered PEPM structure, patient pricing model, and discount guardrails, then reviewing them with your finance and sales leadership. Days 61-90 center on rollout, including account executive training and a documented playbook your team owns moving forward.

We partner directly with finance, commercial leadership, and the person responsible for broker relationships, because pricing decisions in this market involve all three. Your team supplies account-level utilization and cost data, access to ongoing broker and RFP conversations, and participation when pricing changes are communicated to employers or patients.

The cadence is generally a weekly working session throughout the build phase, moving to monthly pricing reviews once the framework goes live, with a dedicated effort around RFP and renewal season because that's when pricing decisions are truly tested.

If your fertility & reproductive health company needs pricing strategy leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

What does a pricing strategy engagement cost for a fertility or reproductive health company?

Pricing strategy engagements generally cost $12,000 to $22,000 per month, depending on the number of employer segments and patient pricing models that must be reconciled. Compare this with the cost of one mispriced enterprise account, which may eliminate more margin in a single plan year than the full engagement costs. Scope and duration are determined by how many pricing models are currently active and how near you are to your next RFP or renewal season.

How soon will we see results from a pricing strategy engagement?

Cost-to-serve and margin visibility work is generally completed within the first 30 days, and that alone often reveals which accounts are unprofitable. The pricing framework is ready to be tested on new deals by day 60, but the true proof point comes during the next renewal or RFP cycle, when the new structure faces actual broker pushback.

How does the pricing team work with our current finance and sales staff?

We partner directly with your finance lead on cost-to-serve modeling, and with sales and account management leadership on the commercial framework, instead of delivering a document for someone else to decipher. Your team retains ownership of pricing decisions; we develop the model, guardrails, and training that make those choices defensible.

What distinguishes Winston Francois from a conventional pricing consultancy?

A generalist pricing consultancy uses a standard SaaS pricing framework that fails to account for a two-sided employer and patient market, or for a finite treatment journey rather than a subscription curve. We design the model around how fertility benefits are actually sold and used, then remain through at least one RFP and renewal cycle to ensure it holds up under real pressure.

How is ROI measured for a pricing strategy engagement?

The main measure is margin per account before and after the engagement, broken down by plan design and utilization tier. We also monitor discount rates throughout RFP season and PEPM retention at renewal, because a pricing framework that withstands a broker-run negotiation is working even before the margin figures catch up.

What kind of fertility or reproductive health company is best suited for this service?

This service is best suited to companies with a live employer benefit book containing at least a handful of accounts, where utilization data is available but hasn't been reconciled with pricing, or to companies approaching a renewal or RFP season without confidence in their existing numbers. Pre-revenue companies that don't yet have employer accounts should prioritize winning their first few deals before developing pricing infrastructure at this level of detail.


Related Solutions

Solutions

Top Articles

Frank Growth – Episode 224 – The Bootstrapper’s Revenge with Alex Roy

Tuesday, June 16, 2026

Frank Growth – Episode 224 – The Bootstrapper’s Revenge with Alex Roy

Episode #224: Alex Roy — Bootstrapping an AI company for 12 years, no funding He founded an AI company in 2014—when AI was a punchline—bootstrapped it with zero outside capital, and landed Fortune 50 clients. For founders and growth operators figuring out how to build (and sell) AI products in a market that shifts every...
Frank Growth – Episode 242 – Why AI Slop Backfires with Nicole Cassese

Tuesday, October 20, 2026

Frank Growth – Episode 242 – Why AI Slop Backfires with Nicole Cassese

Episode #242: Nicole Cassese — Scaling brand voice without burning out the people behind it How to keep a brand voice consistent across 1,600+ assets and still protect the team writing them. For marketing leaders, creative directors, and copywriters running high-volume content with AI in the workflow. Nicole Cassese is the associate creative director owning...
Frank Growth – Episode 245 – The Trojan Horse Sales Strategy with Brian Gilman

Tuesday, November 10, 2026

Frank Growth – Episode 245 – The Trojan Horse Sales Strategy with Brian Gilman

Episode #245: Brian Gilman – Why the funnel breaks when you sell to the C-suite Why meetings, not MQLs, are the number that predicts pipeline on six- and seven-figure deals. For B2B marketers selling mission-critical products to chief risk and compliance officers in regulated industries. Brian Gilman is the CMO of ThetaRay, which sells cognitive...
Frank Growth – Episode 243 – Your Buyer Doesn’t Know They’re Looking with Sandra Moran

Tuesday, October 27, 2026

Frank Growth – Episode 243 – Your Buyer Doesn’t Know They’re Looking with Sandra Moran

Episode #243: Sandra Moran – Selling to a Buyer Who Doesn’t Know They’re Looking How to reposition a category when your new buyer isn’t searching for you yet. For B2B marketers moving from a legacy category to an outcome-based pitch aimed at a new economic buyer. Sandra Moran is CMO at Schoox, a learning platform...

See more

Browse Categories

See more

Ready to unlock your growth?

Book Free Call

We take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.